The Safety And Efficacy Of Sunitinib In Chinese Patients With Progressive Advanced Or Metastatic Well-Differentiated Unresectable Pancreatic Neuroendocrine Tumors
A Multi Center, Prospective, Non Interventional (NI) Study of the Safety and Efficacy of Sunitinib in Chinese Patients With Progressive Advanced or Metastatic Well Differentiated Unresectable Pancreatic Neuroendocrine Tumors
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Beijing, China, 100071
- Fifth Medical Center of PLA General Hospital
-
Beijing, China, 100071
- The PLA of 307 Hospital
-
Shanghai, China, 200032
- Fudan University Shanghai Cancer Center
-
Tianjin, China, 300052
- Tianjin Medical University General Hospital
-
Tianjin, China, 300052
- Tianjin Medical University General Hospital/General Surgery
-
-
Anhui
-
Hefei, Anhui, China, 230061
- Oncology Department, The Second Affiliated Hospital of Anhui Medical University
-
-
Beijing
-
Beijing, Beijing, China, 100021
- Department of Medical Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510060
- Sun Yat-sen University Cancer Center
-
-
Heilongjiang
-
Haerbin, Heilongjiang, China, 150081
- The Affiliated Tumour Hospital of Harbin Medical University
-
-
Henan
-
Zhengzhou, Henan, China, 450052
- The First Affiliated Hospital of Zhengzhou University
-
-
Jiangsu
-
Nanjing, Jiangsu, China, 210002
- Nanjing Bayi Hospital
-
Nanjing, Jiangsu, China, 210029
- Jiangsu Province Hospital
-
Nanjing, Jiangsu, China, 210009
- Jiangsu Cancer Hospital
-
Nanjing, Jiangsu, China, 210002
- General Hospital of Eastern Theater Command
-
Nanjing, Jiangsu, China, 210002
- Nanjing General Hospital of Nanjing Military Command/Hepatobiliary Surgery Department
-
Nanjing, Jiangsu, China, 210002
- Eastern Theater General Hospital,QinHuai District Medical Area
-
-
Shannxi
-
Xi'an, Shannxi, China, 710032
- Digestive surgery Department, The First Affiliated Hospital, The Fourth Military Medical University
-
Xi'an, Shannxi, China, 710032
- The First Affiliated Hospital,Air Force Medical University
-
-
Shanxi
-
Xi'an, Shanxi, China
- Air Force Medical University
-
-
Sichuan
-
Chengdu, Sichuan, China, 610041
- West China Hospital of Sichuan University
-
Chengdu, Sichuan, China, 610041
- West China Hospital of Sichuan University/Hepatobiliary Pancreatic Surgery
-
-
Tianjin
-
Tianjin, Tianjin, China, 300060
- Tianjin Cancer Hospital
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310022
- Zhejiang Cancer Hospital
-
Hangzhou, Zhejiang, China, 310022
- Zhejiang Cancer Hospital, Oncology department
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Evidence of a personally signed and dated informed consent document indicating that the subject (or a legally acceptable representative) has been informed of all pertinent aspects of the study.
- Subjects who are willing to follow up visits within current clinical practice.
- Histologically or cytologically proven diagnosis of well-differentiated pancreatic neuroendocrine tumors (according to WHO 2000 classification)
- Unresectable (as assessed by the investigator) or metastatic disease documented on a scan
- A minimum age of 18 years
Exclusion Criteria:
- Patients with poorly-differentiated pancreatic neuroendocrine tumors (according to WHO 2000 classification)
- Patients who have received at least one dosage of sunitinib treatment prior to signing informed consent form will be excluded from participating in this study.
Study Plan
How is the study designed?
Design Details
- Observational Models: Other
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
sunitinib group
patients with progressive, unresectable, advanced or metastatic well-differentiated pNET
|
subjects will be enrolled to receive at least one dose of sunitinib orally at 37.5 mg once a day on a continuous daily dosing regimen (CDD) or dosage modification is based on daily clinic practice
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) (All Causalities and Treatment-related)
Time Frame: From baseline up to 8 years
|
An adverse event (AE) was any untoward medical occurrence in a participant administered a medicinal product.
The event did not necessarily need to have a causal relationship with the product treatment or usage.
A TEAE was defined as an event that emerged during treatment, having been absent pretreatment, or worsened relative to the pretreatment state.
|
From baseline up to 8 years
|
|
Number of Participants With Serious Adverse Events (SAEs) (All Causalities and Treatment-related)
Time Frame: From baseline up to 8 years
|
An SAE was any untoward medical occurrence in a participant administered a medicinal at any dose that resulted in death; was life-threatening; required inpatient hospitalization or prolongation of hospitalization; resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions); resulted in congenital anomaly/birth defect.
|
From baseline up to 8 years
|
|
Number of Participants With Hematology/Chemistry/Urinalysis Laboratories of Baseline Common Terminology Criteria for Adverse Events (CTCAE) Grade ≤2 at Baseline That Shifted to a Maximum CTCAE Grade 3 or 4
Time Frame: From baseline up to 8 years
|
Laboratory abnormalities assessment included: hematologic: hemoglobin, platelet count, white blood cell (WBC) count, neutrophile granulocyte count; non-hematologic: total bilirubin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase, gamma-glutamyl transferase (GGT), total protein, albumin, blood urea nitrogen (BUN), creatinine, uric acid, glucose, hypocalcemia, hyponatremia, hypophosphatemia, hypokalaemia.
|
From baseline up to 8 years
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Progression-Free Survival (PFS)
Time Frame: From baseline up to 8 years
|
Investigator assessed PFS according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.6.
PFS was defined as the time from the start of sunitinib treatment to first document of objective tumor progression or death due to any cause, whichever occurred first.
Progression was defined using RECIST v1.0, as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
|
From baseline up to 8 years
|
|
Progression-Free Survival by Clinical Judgment
Time Frame: From baseline up to 8 years
|
PFS by clinical judgment was defined as the time from the start of sunitinib treatment to first document of objective tumor progression, or first time tumor progression diagnosed by investigator based on clinical judgment, or death due to any cause, whichever occurred first.
Progression was defined using RECIST v1.0, as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
|
From baseline up to 8 years
|
|
Overall Survival (OS)
Time Frame: From baseline up to 8 years
|
OS was defined as the time from the start of sunitinib treatment to documentation of death due to any cause.
|
From baseline up to 8 years
|
|
Five-Year Survival Rate
Time Frame: From baseline up to 8 years
|
Five-year survival rate was defined as the proportion of participants who stayed alive till after 5 years from the start of sunitinib treatment.
|
From baseline up to 8 years
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Pfizer CT.gov Call Center, Pfizer
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimated)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Neoplasms, Glandular and Epithelial
- Endocrine System Diseases
- Digestive System Neoplasms
- Endocrine Gland Neoplasms
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Pancreatic Diseases
- Adenoma
- Pancreatic Neoplasms
- Neuroendocrine Tumors
- Adenoma, Islet Cell
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Protein Kinase Inhibitors
- Sunitinib
Other Study ID Numbers
Other Study ID Numbers
- A6181215
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.